Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
about
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsPrediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolidHigh plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.A commentary on the disparate perspectives of clinical microbiologists and surgeons: ad hoc antimicrobial use.Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational studyAntibiotic options for treating community-acquired MRSA.Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersUpdate on the safety of linezolid.Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisIn vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding.In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptidesLack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.The pharmacokinetics of linezolid in the non-inflamed human eye.Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Role of linezolid in the treatment of orthopedic infections.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelApplicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression ModelsPharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.Use of linezolid in children: an overview of recent advances.Linezolid for the treatment of patients with central nervous system infection.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Linezolid: effectiveness and safety for approved and off-label indications.In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.Current challenges in treating MRSA: what are the options?Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.
P2860
Q26853629-841F49D2-1805-4A4A-B3AA-2B1D7F5AA0FAQ30947691-96E2312C-57FD-4EC4-BBD5-0DADED860265Q33375091-8435E0FC-1E34-4AFC-A601-9D570C8334E9Q33407349-7E2715C7-7DF9-4CA3-B467-6131167273C0Q33836578-D2A59C95-B53D-46DB-AEE4-210E6959ABFEQ33935469-6DC15413-58AD-41DE-B3BD-FBADCFD167BDQ34075826-DB8180A8-7C7E-4445-801E-2A8DC46A8626Q34486095-CE75CA86-9DA0-4F99-BE85-D81054F7C820Q34593646-18711D56-0AFF-489E-BC2F-ABB7AC12CF3EQ34596658-C4AED759-F474-422A-B644-E3BF95E97E6AQ34638260-F52D223C-7BB4-47BA-BBE7-75C943E85153Q34987632-8EEA10E9-BC4B-4849-B2D3-8DD4EE5DBE09Q35065732-1CF53D22-2A6A-4DB6-BF39-47AD5B8D9202Q35065908-696356C0-536C-4038-A597-A83A7BA4A751Q35081931-2B1A63E4-925C-4326-8AC1-5D1FAEA3B644Q35083990-C345356B-39C1-4139-B6F2-FA9CB7DF90C7Q35191408-42B8FA70-6F4D-468A-B7BB-E84B11B61FEBQ35215457-675A8E02-1F19-48B4-A121-AD6604208249Q35593858-F7FCEE62-25CE-46CC-B67C-CD3B88A766BAQ35635671-7D438E69-0437-4F5A-B3DC-9F4942672E2DQ35964560-8011CEA6-9E6C-4E54-8C59-58405C2E795EQ36083208-88F91E43-4303-44F8-953E-0E1B211916B5Q36162348-63AEB309-19A7-4484-8718-05EF2DE09C0DQ36171683-0B86DAD2-49E3-4E1D-9E8D-7111D6433394Q36172366-6DE8FB9B-644B-49F5-A68E-F6AFFBE9F504Q36364009-2A09EDD6-0D9E-4737-8918-7111A844F59DQ36620071-5981D73F-AC71-4FFD-BA57-04319D48DA89Q36667074-65CB6983-4F4E-4651-B76E-3477551C4C3AQ36688930-9699224D-3606-436A-A5BF-795376B1BDBCQ36729811-ED874247-6B5D-4B78-8314-2A7826593B7AQ36777850-1F3042C7-C8D3-4E6E-A234-786D642F3978Q36967288-EEE7B642-2F12-4105-99AD-7FDC02F55CF5Q37190797-9BC9D54A-E2E5-48FB-A116-5E0C1385089FQ37291338-A20855D1-F828-4A23-A3F2-C51864F621DAQ37339276-28C4DE75-CF1E-4775-8C0E-11FD39127826Q37377897-586727C2-2F17-44C5-A976-F2124C845697Q37568382-12FC2941-70AC-48FF-9032-32CAFF09D2D4Q37747401-18BA2025-4D38-4B0D-9217-FC6E917AE2FCQ37869258-DF66C6B1-E568-4717-A597-801CBA6077D6Q38070154-0F132288-0C56-4381-B957-BFF08F341FC8
P2860
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@ast
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@en
type
label
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@ast
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@en
prefLabel
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@ast
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@en
P356
P1476
Pharmacokinetic and pharmacody ...... with Gram-positive infections.
@en
P2093
Alasdair P MacGowan
P304
P356
10.1093/JAC/DKG248
P407
P478
51 Suppl 2
P577
2003-05-01T00:00:00Z